Cargando…

Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials

BACKGROUND & AIMS: Platinum-based drugs are the most significant chemotherapy for advanced gastric cancer. The study aims to compare the efficacy and safety of oxaliplatin-based therapy versus cisplatin-based therapy in patients with advanced gastric cancer. MATERIALS AND METHODS: An adequate li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jun, Zhao, Yongzhao, Xu, Yong, Zhu, Yanjie, Huang, Jiale, Liu, Yanna, Zhao, Liying, Li, Zhijia, Liu, Hao, Wang, Qi-long, Qi, Xiaolong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085192/ https://www.ncbi.nlm.nih.gov/pubmed/27166187 http://dx.doi.org/10.18632/oncotarget.9189

Ejemplares similares

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
por: Liu, Peng, et al.
Publicado: (2022)

Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study
por: Chinen, Takashi, et al.
Publicado: (2022)

A predictive signature for oxaliplatin and 5-fluorouracil based chemotherapy in locally advanced gastric cancer
por: Wang, Qinchuan, et al.
Publicado: (2020)

Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis
por: Zhang, Fei, et al.
Publicado: (2019)

Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer
por: Yamada, Yasuhide, et al.
Publicado: (2019)

Prognostic and Predictive Value of p21-activated Kinase 6 Associated Support Vector Machine Classifier in Gastric Cancer Treated by 5-fluorouracil/Oxaliplatin Chemotherapy
por: Jiang, Yuming, et al.
Publicado: (2017)

Management of advanced gastric cancer: An overview of major findings from meta-analysis
por: Qi, Xiaolong, et al.
Publicado: (2016)

Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma
por: Liu, Ying, et al.
Publicado: (2013)

PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis
por: Guo, Xiaoyu, et al.
Publicado: (2022)

Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins
por: LIU, YONGPING, et al.
Publicado: (2015)

The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial
por: Ahmadzadeh, Ahmad, et al.
Publicado: (2020)

PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer
por: Huang, Weicai, et al.
Publicado: (2022)

Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial
por: Yu, Jiren, et al.
Publicado: (2022)

Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer
por: Yu, Jing, et al.
Publicado: (2015)

Circ-104916 is downregulated in gastric cancer and suppresses migration and invasion of gastric cancer cells
por: Li, Jin, et al.
Publicado: (2017)

Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro
por: Zhao, Qun, et al.
Publicado: (2010)

Feasibility and Safety of Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel for Locally Advanced Gastric Cancer Patients in China
por: Sah, Birendra Kumar, et al.
Publicado: (2021)

Genetic Polymorphism of GSTP1: Prediction of Clinical Outcome to Oxaliplatin/5-FU-based Chemotherapy in Advanced Gastric Cancer
por: Li, Qing-Fang, et al.
Publicado: (2010)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes
por: Qi, Guoyan, et al.
Publicado: (2017)

Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis
por: Ostwal, Vikas, et al.
Publicado: (2017)

Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies
por: Liu, Lin, et al.
Publicado: (2016)

Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
por: Lee, Min Jeong, et al.
Publicado: (2012)

Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin
por: Ren, Li-Qun, et al.
Publicado: (2020)

Effect of oxaliplatin combined with polyenephosphatidylcholine on the proliferation of human gastric cancer SGC-7901 cells
por: Jiang, Tao, et al.
Publicado: (2016)

Phase IIb study of pembrolizumab combined with S‐1 + oxaliplatin or S‐1 + cisplatin as first‐line chemotherapy for gastric cancer
por: Yamaguchi, Kensei, et al.
Publicado: (2022)

EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells
por: Wen, Qiaocheng, et al.
Publicado: (2017)

Choice of Capecitabine or S1 in Combination with Oxaliplatin based on Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase Expression Status in Patients with Advanced Gastric Cancer
por: Xu, Rong, et al.
Publicado: (2019)

Long-term platinum retention after treatment with cisplatin and oxaliplatin
por: Brouwers, Elke EM, et al.
Publicado: (2008)

Does Doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer?
por: Sagar, Jayesh, et al.
Publicado: (2009)

Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibody Treatments
por: Mehmood, Rao Khalid
Publicado: (2014)

Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective
por: Mehmood, Rao Khalid, et al.
Publicado: (2014)

Oxaliplatin related lncRNAs prognostic models predict the prognosis of patients given oxaliplatin-based chemotherapy
por: Zhou, Qing-nan, et al.
Publicado: (2023)

Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer
por: Zhang, Yonglei, et al.
Publicado: (2021)

The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy
por: LIU, YONG-PING, et al.
Publicado: (2013)

Survival benefit of gastrectomy for gastric cancer with peritoneal carcinomatosis: a propensity score‐matched analysis
por: Geng, Xiuwen, et al.
Publicado: (2016)

The Safety and Feasibility of Laparoscopic Gastrectomy after Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
por: Ge, Rui, et al.
Publicado: (2022)

Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy: A retrospective cohort study
por: Su, Jin, et al.
Publicado: (2022)

Prognostic Significance of miR-181b and miR-21 in Gastric Cancer Patients Treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin
por: Jiang, Jingting, et al.
Publicado: (2011)

Cisplatin and Oxaliplatin Toxicity: Importance of Cochlear Kinetics as a Determinant for Ototoxicity
por: Hellberg, Victoria, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_bla20s96q963l9v09rsjol1mi8